

CLINICAL—LIVER

Elafibranor, an Agonist of the Peroxisome Proliferator – Activated Receptor – α and – δ , Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening

Vlad Ratziu,^{1,2} Stephen A. Harrison,³ Sven Francque,⁴ Pierre Bedossa,⁵ Philippe Leheret,^{6,7} Lawrence Serfaty,⁸ Manuel Romero-Gomez,⁹ Jérôme Boursier,¹⁰ Manal Abdelmalek,¹¹ Steve Caldwell,¹² Joost Drenth,¹³ Quentin M. Anstee,¹⁴ Dean Hum,¹⁵ Remy Hanf,¹⁵ Alice Roudot,¹⁵ Sophie Megnier,¹⁵ Bart Staels,¹⁶ and Arun Sanyal,¹⁷ on behalf of the GOLDEN-505 Investigator Study Group

¹Université Pierre et Marie Curie, Hôpital Pitié Salpêtrière, Paris, France; ²Institute of Cardiometabolism and Nutrition, INSERM, UMRS 938, Paris, France; ³Department of Medicine, Gastroenterology and Hepatology Service, Brooke Army Medical Center, Fort Sam Houston, Texas; ⁴Department of Gastroenterology and Hepatology, Antwerp University Hospital, University of Antwerp, Antwerp, Belgium; ⁵Department of Pathology, Hôpital Beaujon, University Paris-Denis Diderot, Paris, France; ⁶Department of Psychiatry, the University of Melbourne, Melbourne, Australia; ⁷Faculty of Economics, University of Louvain UCL, Belgique, Belgium; ⁸Université Pierre et Marie Curie, Hôpital Saint-Antoine, Paris, France; ⁹Unit for the Clinical Management of Digestive Diseases and CIBERehd, Hospital Universitario de Valme, Sevilla; ¹⁰Hepatology Department, University Hospital and LUNAM University, Angers, France; ¹¹Duke University, Durham, North Carolina; ¹²Gastroenterology and Hepatology Division, University of Virginia, Charlottesville, Virginia; ¹³Department of Gastroenterology and Hepatology, Radboud University Medical Center, Nijmegen, The Netherlands; ¹⁴Institute of Cellular Medicine, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, UK; ¹⁵Genfit SA, Loos, France; ¹⁶University of Lille, INSERM UMR1011, Institut Pasteur de Lille, European Genomic Institute for Diabetes, Lille, France; and ¹⁷Virginia Commonwealth University, Richmond, Virginia

See editorial on page 1073.

BACKGROUND & AIMS: Elafibranor is an agonist of the peroxisome proliferator–activated receptor- α and peroxisome proliferator–activated receptor- δ . Elafibranor improves insulin sensitivity, glucose homeostasis, and lipid metabolism and reduces inflammation. We assessed the safety and efficacy of elafibranor in an international, randomized, double-blind placebo-controlled trial of patients with nonalcoholic steatohepatitis (NASH). **METHODS:** Patients with NASH without cirrhosis were randomly assigned to groups given elafibranor 80 mg (n = 93), elafibranor 120 mg (n = 91), or placebo (n = 92) each day for 52 weeks at sites in Europe and the United States. Clinical and laboratory evaluations were performed every 2 months during this 1-year period. Liver biopsies were then collected and patients were assessed 3 months later. The primary outcome was resolution of NASH without fibrosis worsening, using protocol-defined and modified definitions. Data from the groups given the different doses of elafibranor were compared with those from the placebo group using step-down logistic regression, adjusting for baseline nonalcoholic fatty liver disease activity score. **RESULTS:** In intention-to-treat analysis, there was no significant difference between the elafibranor and placebo groups in the protocol-defined primary outcome. However, NASH resolved without fibrosis worsening in a higher proportion of patients in the 120-mg elafibranor group vs the placebo group (19% vs 12%; odds ratio = 2.31; 95% confidence interval: 1.02–5.24; $P = .045$), based on a post-hoc analysis for the modified definition. In post-hoc analyses of patients with nonalcoholic fatty liver disease activity score ≥ 4 (n = 234), elafibranor 120 mg resolved NASH in larger proportions of patients than placebo based on the protocol definition (20% vs 11%; odds ratio = 3.16; 95% confidence interval: 1.22–8.13; $P = .018$) and

the modified definitions (19% vs 9%; odds ratio = 3.52; 95% confidence interval: 1.32–9.40; $P = .013$). Patients with NASH resolution after receiving elafibranor 120 mg had reduced liver fibrosis stages compared with those without NASH resolution (mean reduction of 0.65 ± 0.61 in responders for the primary outcome vs an increase of 0.10 ± 0.98 in nonresponders; $P < .001$). Liver enzymes, lipids, glucose profiles, and markers of systemic inflammation were significantly reduced in the elafibranor 120-mg group vs the placebo group. Elafibranor was well tolerated and did not cause weight gain or cardiac events, but did produce a mild, reversible increase in serum creatinine (effect size vs placebo: increase of $4.31 \pm 1.19 \mu\text{mol/L}$; $P < .001$). **CONCLUSIONS:** A post-hoc analysis of data from trial of patients with NASH showed that elafibranor (120 mg/d for 1 year) resolved NASH without fibrosis worsening, based on a modified definition, in the intention-to-treat analysis and in patients with moderate or severe NASH. However, the predefined end point was not met in the intention to treat population. Elafibranor was well tolerated and improved patients' cardiometabolic risk profile. ClinicalTrials.gov number: NCT01694849.

Keywords: PPARA; PPAR δ ; NAFLD; fatty liver.

Abbreviations used in this paper: bNAS, baseline NAS; CI, confidence interval; HDL, high-density lipoprotein; HOMA-IR, Homeostasis Model Assessment Index–Insulin Resistance; ITT, intention to treat; NAFLD, nonalcoholic fatty liver disease; NAS, nonalcoholic fatty liver disease activity score; NASH, nonalcoholic steatohepatitis; OR, odds ratio; PPAR, peroxisome proliferator–activated receptor.

Most current article

© 2016 by the AGA Institute Open access under [CC BY-NC-ND license](https://creativecommons.org/licenses/by-nc-nd/4.0/). 0016-5085

<http://dx.doi.org/10.1053/j.gastro.2016.01.038>

Of all chronic liver diseases, nonalcoholic steatohepatitis (NASH) is of increasing concern, as it is highly prevalent, potentially severe and without approved therapy. NASH defines a subgroup of nonalcoholic fatty liver disease where liver steatosis coexists with hepatic cell injury (apoptosis and hepatocyte ballooning), and inflammation.¹ It occurs in close association with overweight/obesity, type 2 diabetes, and cardiometabolic conditions that define the metabolic syndrome.² Because of the prevalence of these comorbidities, NASH is emerging as the most common chronic liver disease.

NASH promotes liver fibrosis and some patients progress to severe hepatic diseases, including cirrhosis, liver failure, hepatocellular carcinoma, or require liver transplantation.^{3,4} Liver-related mortality is increased 10-fold in NASH patients compared with the general population.⁵ However, NASH is also a multisystem disease that could worsen insulin resistance, the metabolic syndrome, and the systemic inflammatory state.⁶ Consequently, NASH patients also have an increased rate of cardiovascular events and neoplasia. These 2 latter conditions carry the heaviest toll in terms of mortality, the leading cause of death being from cardiovascular events.^{3,7,8}

Peroxisome proliferator-activated receptors (PPARs) are nuclear receptors playing key roles in cellular processes regulating metabolic homeostasis, immune-inflammation, and differentiation. PPAR γ agonists demonstrated efficacy in improving histology in NASH,⁹⁻¹¹ but side effects, such as congestive heart failure, peripheral edema, bone fractures, and weight gain severely restrict their prescription and acceptance as long-term therapies. PPAR α is most prominently expressed in the liver and is activated by hypolipidemic fibrates. PPAR α controls the lipid flux in the liver by modulating fatty acid transport and β -oxidation, while improving plasma lipids by decreasing triglycerides and increasing high-density lipoprotein (HDL) cholesterol.¹² In addition, PPAR α activation inhibits inflammatory genes induced by nuclear factor- κ B and decreases the expression of acute-phase response genes.¹² PPAR δ (also called PPAR β) regulates metabolism in liver and peripheral tissues. PPAR δ agonists enhance fatty acid transport and oxidation, increase HDL levels, and improve glucose homeostasis by enhancing insulin sensitivity and inhibiting hepatic glucose output.¹³ Importantly, PPAR δ exerts anti-inflammatory activities in macrophages and Kupffer cells.¹⁴ In a pilot trial, a selective PPAR δ agonist reduced liver fat content, while improving insulin sensitivity, plasma lipids, and decreasing γ -glutamyltransferase.¹⁵

Elafibranor (GFT505) is a dual PPAR α/δ agonist that has demonstrated efficacy in disease models of nonalcoholic fatty liver disease (NAFLD)/NASH and liver fibrosis.¹⁶ Elafibranor confers liver protection by acting on several pathways involved in NASH pathogenesis, reducing steatosis, inflammation, and fibrosis. In phase 2a trials in dyslipidemic, prediabetic and type 2 diabetic patients, elafibranor consistently improved plasma lipids and glucose homeostasis, peripheral and hepatic insulin resistance, and reduced liver inflammatory markers.^{17,18}

This phase II study was conducted to assess the efficacy of elafibranor for NASH in an international, randomized, placebo-controlled, multicenter, 1-year clinical trial.

Methods

Study Design

This international, multicenter, randomized placebo-controlled study tested elafibranor at the dose of 80 mg and 120 mg once a day vs placebo over 52 weeks and was conducted at 56 sites, 19 in the United States and 37 in 8 European countries. The study had a staggered design as requested by the regulatory agencies to test the safety of elafibranor during a 6-month period at the lower dose before exposing patients for 1 year at the highest dose. During the first recruitment phase, 172 patients were screened between September 2012 and June 2013 for treatment with 80 mg/d of elafibranor or placebo (allocation 2:1). The second recruitment period at the dose of 120 mg/d started in July 2013, when 179 patients were screened in 1 week. The randomization of this second cohort started in October 2013 (allocation of elafibranor 120 mg or placebo in a 2:1 ratio), after unrestricted approval from the Independent Data and Safety Monitoring Board. The clinical study protocol was approved in all countries by National Authorities and Ethics Committees. All patients gave written informed consent. All authors had access to the study data and have approved and reviewed the final manuscript.

Patients

The inclusion criteria included age 18 to 75 years and a histologic diagnosis of noncirrhotic NASH confirmed by a central pathologist. Patients were excluded if daily alcohol consumption was more than 2 drink units/d (equivalent to 20 g) in women and 3 drink units/d (30 g) in men, if steatohepatitis was due to secondary causes, or if any other chronic liver disease was identified.

Randomization and Masking

Randomization was obtained through a computer-generated coding list, and treatment allocation was performed centrally for all sites through a web system, based on date of randomization, and stratified for diabetes. No stratification was made on investigation sites. Elafibranor and placebo were provided as identical capsules in wallets labeled with code numbers. Patients, investigators, clinical site staff, and the pathologist were masked to treatment assignment. The allocation of treatment was done in a 1:1:1 ratio for the 3 treatment arms—placebo, elafibranor 80 mg, and elafibranor 120 mg.

Procedures

Patients were followed every 2 months with clinical and laboratory evaluations throughout the 1-year treatment period. An end-of-treatment biopsy and a 3-month post-treatment follow-up visit were performed. Screening and end-of-treatment biopsies were all read centrally by a single pathologist in a blinded manner (PB). At end of study, all slides (baseline and end of study) were read in scrambled order. For inclusion, the liver biopsy needed to be collected within the

past 9 months. Steatohepatitis was diagnosed based on the presence of steatosis (>5% of hepatocytes), hepatocyte ballooning, and lobular inflammation. Fibrosis was evaluated using the NASH CRN fibrosis staging system. Included patients had an NAFLD activity score (NAS) ranging from 3 to 8, with at least 1 for steatosis, ballooning, and inflammation. All stages of fibrosis (0–3) were accepted, except for cirrhosis. Noninvasive panels for steatosis or fibrosis (Fatty Liver Index, SteatoTest, Fibrotest, and the NAFLD Fibrosis score) were measured at baseline, 6 months, and 12 months (end of treatment). Biologic assessments were all centralized and performed at each visit for efficacy and safety purposes.

Outcomes

The primary outcome was reversal of NASH without worsening of fibrosis. This was defined as per protocol, before study start, as the absence (score of 0) of at least 1 of the 3 components of NASH, that is, steatosis, ballooning, and inflammation; worsening of fibrosis was defined as the progression to bridging fibrosis (ie, stage 3) or cirrhosis in patients without bridging fibrosis at baseline or to cirrhosis in patients with bridging fibrosis at baseline.

After the study was completed, a modified and more stringent definition was proposed by academic and regulatory experts and recommended by regulatory agencies for ongoing trials.^{19,20} It defines resolution of NASH as disappearance of ballooning (score = 0), together with either disappearance of lobular inflammation or the persistence of mild lobular inflammation only (score = 0 or 1), and resulting in an overall pathologic diagnosis of either steatosis alone or steatosis with mild inflammation; any stage increase in fibrosis is considered fibrosis progression. Because this more stringent definition is now used for current and future trials, we will here report on both the protocol-defined and the post-hoc analysis of the modified definition.

Secondary outcomes included changes in NAS between end of treatment and baseline biopsy (including the proportion of patients with a 2-point decrease); changes and improvements in individual histologic scores of steatosis, ballooning, inflammation, and fibrosis; changes in liver enzymes, in noninvasive markers of steatosis and fibrosis, in lipid and glycemic parameters, in surrogate markers of insulin resistance (fasting insulin and Homeostasis Model Assessment Index scores); changes in systemic inflammatory markers; and safety and tolerability of elafibranor at both doses.

Statistical Methods

The main selection was the population of all randomized patients that received at least one dose of study drug (intention-to-treat [ITT] sample). To assess the robustness of findings, sensitivity analyses were performed using the per-protocol population defined as the ITT population with available liver biopsy at the end of the study. For sensitivity purposes, the following post-hoc selections were considered: patients with baseline NAS (bNAS) ≥ 4 (moderate or high disease activity), who are similar to those included in previous NASH trials^{11,21}; patients with bNAS ≥ 4 and fibrosis of any stage at baseline; patients with bNAS ≥ 4 and fibrosis stage ≥ 2 at baseline (target patient population for current phase 3 trials), and patients with bNAS ≥ 4 recruited in centers that

randomized at least 1 patient in each treatment arm (justified by the strong treatment-center imbalance). The ITT population was the main selection and a significant effect observed in the ITT population was conditional to test the significance in the other subpopulations.

The main analysis was a mixed model featuring logistic regression on therapy response with treatment as fixed factor (placebo, 80 mg, and 120 mg), adjusted for bNAS. The multi-center context was accounted for by random factor. Based on the assumption of superiority of the 120-mg dose, testing the 80-mg dose was conditional to the significance of the effect of 120 mg (step-down testing²²). No multiplicity correction was needed due to step-down strategy.²² For patients with liver biopsy unavailable at the end of treatment, a worst-case imputation in assimilating missing value to therapy failure was considered.

Post-hoc analyses tested the main treatment effect and its interaction with baseline severity (bNAS).

For easier clinical discussion, risk ratio was reported with odds ratio (OR) derived from logistic regression. Geometric mean change over baseline and related *t* tests were used to compare the treatment subgroups on biologic parameters, composite biomarker scores for NAFLD and fibrosis.

For sample size calculations, we assumed a 20% and 45% responder rate in the placebo and 120-mg dose groups, respectively, and a dropout rate of 25%. Ninety patients per group were required to reach this difference, with a power of 80% at a 2-sided .05 significance test level. The analyses were conducted with the Statistical Package R (release 3.1.1), all tests were conducted at .05 two-sided level.

Role of the Funding Source

The GOLDEN-505 study was sponsored by Genfit SA. The protocol was written by a panel of academic experts and sponsor representatives and amended in accordance to input from regulatory bodies. The corresponding author had full access to all the data in the study and had final responsibility for manuscript submission.

Results

A total of 276 patients were randomized, 92 in the placebo group, 93 in the elafibranor 80 mg group, and 91 in the elafibranor 120-mg group (Figure 1). Two patients did not receive the study medication and the remaining 274 patients constitute the ITT population. Thirty-three patients (12%) dropped out during the study (Supplementary Table 1). Final liver biopsies were available in 237 patients (77, 82, and 78 patients in the placebo, elafibranor 80 mg, and elafibranor 120 mg groups, respectively). Of these, only 5 patients were no longer diagnosed as having NASH on the baseline biopsy upon scrambled re-reading at end of study. This did not modify the overall results.

Table 1 shows the baseline characteristics across treatment groups. The elafibranor arms contained fewer Caucasians, fewer men, more diabetics, and overall higher Homeostasis Model Assessment Index–Insulin Resistance (HOMA-IR) and insulin levels than the placebo group.

Table 2 shows the response rates and corresponding risk ratios in the ITT population for the primary outcome.




Figure 1. Trial profile. ITT, intention to treat; PP, per protocol.

There was no difference between the elafibranor arms and placebo according to the protocol-defined definition. A post-hoc analysis using the modified definition of response shows that the response rate was significantly higher for the 120-mg arm than for placebo (19% vs 12%; OR = 2.31; 95% confidence interval [CI]: 1.02–5.24; $P = .045$). The 80-mg arm did not perform better than placebo for both definitions of response, the protocol-based and the modified definition (OR = 1.48; 95% CI: 0.7–3.14; $P = .30$ and 1.11, 95% CI: 0.48–2.57; $P = .80$, respectively), or for any other histologic analysis.

Results of the secondary histologic outcomes (Supplementary Table 3) show no significant difference between elafibranor and placebo. Nonetheless, the efficacy of the 120-mg dose to reduce the NAS by 2 points and to improve steatosis, ballooning, and lobular inflammation was more pronounced with increasing baseline severity, in contrast to the absence of a clear pattern in the placebo or 80-mg groups.

A number of post-hoc, secondary analyses were performed. Importantly, there was a strong interaction effect between baseline severity and elafibranor dose, which was significant for 120 mg for both the protocol-defined (OR = 2.63; 95% CI: 1.25–5.52; $P = .012$) and modified definition (OR = 2.76; 95% CI: 1.33–5.76; $P = .007$) (Supplementary Table 2). The significant interaction effect with baseline severity indicated that the efficacy of elafibranor 120 mg vs placebo increased with baseline severity. Hence, the exclusion of patients with mild disease activity (bNAS = 3, $n = 40$) revealed a significant direct effect of elafibranor 120 mg vs placebo (OR = 3.16; 95% CI: 1.22–8.13 and OR = 3.52; 95% CI: 1.32–9.40, for the protocol-defined and modified definitions, respectively) in the remaining population of 234 patients with bNAS ≥ 4 (85% of the ITT population); there was no significant difference for the 80-mg arm. Overall, the 120-mg elafibranor dose doubled the proportion of responders vs placebo in patients with bNAS ≥ 4 .

Table 1. Baseline Characteristics of the Study Population (ITT)

Characteristic	Placebo (n = 92)	Elafibranor, 80 mg (n = 93)	Elafibranor, 120 mg (n = 89)
Demographics			
Age, y, mean (SD)	52.4 (11.9)	52.7 (11.0)	52.4 (11.6)
Male, %	60	53	53
Race, Caucasian, %	92.4	94.6	79.8
BMI, kg/m ² , mean (SD)	30.9 (4.2)	31.8 (5.2)	31.0 (4.4)
Weight, kg, mean (SD)	88.7 (16)	89.6 (17.8)	90.2 (15.6)
Waist circumference, cm, mean (SD)	104.7 (10.5)	106.4 (13.1)	106.3 (10.3)
Comorbidities, n (%)			
Type 2 diabetes	33 (36)	37 (40)	37 (42)
Arterial hypertension	43 (47)	47 (50)	55 (62)
Hyperlipidemia	50 (54)	46 (49)	58 (65)
Cardiovascular disease	5 (5)	5 (5)	6 (7)
Concomitant medications, n (%)			
Metformin	30 (32.6)	30 (32.3)	34 (38.2)
Insulin	9 (9.8)	15 (16.1)	7 (7.9)
Statins	31 (33.7)	28 (30.1)	33 (37.1)
Vitamin E ≤400 UI/d	0 (0)	2 (2.2)	3 (3.4)
PUFA ≤2 g/d	5 (5.4)	5 (5.4)	10 (11.2)
Biology, mean (SD)			
ALT, U/L	63.8 (39.9)	60.7 (40.2)	63.8 (43.7)
AST, U/L	44.5 (28.6)	40.9 (27.0)	41.7 (23.8)
GGT, U/L	80.1 (102.8)	75.1 (69.0)	66.7 (65.4)
Alkaline phosphatase, U/L	76.8 (22.7)	73.8 (23.4)	77.5 (21.0)
Total bilirubin, mg/dL	10.0 (5.9)	9.6 (5.4)	10.5 (8.5)
Triglycerides, mmol/L	1.8 (1.1)	1.8 (0.9)	2.0 (1.1)
Total cholesterol, mmol/L	4.8 (1.1)	5.1 (1.2)	4.8 (1.1)
HDL cholesterol, mmol/L	1.3 (0.3)	1.3 (0.4)	1.2 (0.3)
LDL cholesterol, mmol/L	2.8 (0.9)	3.0 (1.0)	2.7 (0.9)
Fasting glucose, mmol/L	5.8 (1.5)	6.1 (2.1)	6.2 (2.1)
Fasting insulin, pmol/L	154.2 (80)	193.9 (205)	180.3 (144)
HOMA-IR	5.9 (3.9)	8.4 (10.9)	7.6 (8.1)
HbA1c, %	6.0 (0.8)	6.0 (0.9)	6.2 (1.1)
Fibrinogen, g/L	3.3 (0.6)	3.2 (0.7)	3.4 (0.8)
Haptoglobin, g/L	1.24 (0.6)	1.30 (0.5)	1.30 (0.6)
Alpha 2 macroglobulin, g/L	2.26 (0.97)	2.28 (0.82)	2.39 (0.84)
Histology, mean (SD)			
Median time interval historic biopsy inclusion, d	79.4 (67.7)	110.7 (86.1)	58.2 (50.9)
NAS, n (%)	5.0 (1.3)	5.0 (1.2)	4.9 (1.3)
NAS = 3	16 (17.4)	10 (10.8)	14 (15.7)
NAS 4–5	45 (48.9)	54 (58.0)	45 (50.6)
NAS 6–8	31 (33.7)	29 (31.2)	30 (33.7)
Hepatocyte ballooning	1.4 (0.5)	1.4 (0.5)	1.4 (0.5)
Lobular inflammation grade	1.4 (0.6)	1.4 (0.6)	1.4 (0.5)
Steatosis grade	2.2 (0.7)	2.3 (0.8)	2.2 (0.8)
Fibrosis stage, n (%)			
0	15 (16.3)	20 (21.5)	5 (5.6)
1	32 (34.8)	28 (30.1)	39 (43.8)
2	25 (27.2)	22 (23.7)	25 (28.1)
3 (bridging fibrosis)	20 (21.7)	23 (24.7)	20 (22.5)

ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI, body mass index; GGT, γ -glutamyltransferase; LDL, low-density lipoprotein; PUFA, polyunsaturated fatty acid.

As patient recruitment was based on a wide spectrum of baseline severity (NAS 3–8 and fibrosis stage 0–3), we performed post-hoc analyses in NAS ≥ 4 populations with increasing fibrosis stages (Table 3). The response rates of 120 mg elafibranor for the protocol-defined definition were significantly higher than that of placebo, while there was no significant difference for the 80-mg arm. The 120-mg dose

was also more effective in the subpopulation of patients with any fibrosis (F1–F3), as well as in those with moderate or advanced fibrosis (F2–F3) (Table 3). The results were qualitatively similar when using the modified definition (data not shown).

Because of a heterogeneous center effect and the unbalanced treatment-center distribution (due to the

Table 2. Response Rates and Main Analyses According to Protocol-Defined and the Modified Definitions of Response

NAS	n	Placebo, n (%)	Elafibranor 80 mg, n (%)	Elafibranor 120 mg, n (%)	OR (95% CI) ^a	P value ^a
Protocol-defined primary outcome						
Total	274	92 (17)	93 (23)	89 (21)	1.53 (0.70–3.34)	.280
NAS ≥4 (moderate and severe)	234	76 (11)	83 (20)	75 (20)	3.16 (1.22–8.13)	.018
NAS 3 (mild)	40	16 (50)	10 (40)	14 (29)		
Modified definition of response						
Total	274	92 (12)	93 (13)	89 (19)	2.31 (1.02–5.24)	.045
NAS ≥4 (moderate and severe)	234	76 (9)	83 (13)	75 (19)	3.52 (1.32–9.40)	.013
NAS 3 (mild)	40	16 (25)	10 (10)	14 (21)		

^aElafibranor 120 mg vs placebo, direct treatment effect.

staggered design and an unexpected high rate of recruitment), we performed an analysis in the subset of bNAS ≥4 patients recruited in centers that randomized at least 1 patient in each treatment arm (n = 120, [Supplementary Table 4](#)). The response rates were 29% and 26% (protocol-defined and modified definitions) vs 5% placebo (P = .01 and .02, respectively). Forty-eight percent of patients improved the NAS by ≥2 points (vs 21% in the placebo arm; P = .013). Hepatocyte ballooning and lobular inflammation were also significantly improved, with a trend toward improvement in steatosis but not fibrosis.

Finally, we tested whether patients that achieved resolution of NASH without worsening of fibrosis in the 120-mg elafibranor arm also experienced improvement in fibrosis. [Supplementary Figure 1](#) shows strong reductions in fibrosis, hepatocyte ballooning, and the NAS (all P < .001), as well as in lobular inflammation and steatosis (both P < .05), when compared with nonresponders to the same regimen. These findings were similar with both definitions of response.

Patients treated with both elafibranor doses (80 mg and 120 mg) improved liver function tests (alanine aminotransferase, γ-glutamyltransferase, and alkaline phosphatase; [Figure 2A–C](#)) and lipid parameters (triglycerides, low-density lipoprotein cholesterol, HDL cholesterol, [Figure 2D–F](#)). In diabetic patients (40% of the Intention to Treat population), elafibranor improved fasting serum

glucose (−0.98 ± 0.56 mmol/L for 120 mg vs placebo; P = .08) and HbA1c (−0.46% for 120 mg vs placebo; P = .038), as well as markers of insulin resistance (fasting insulin, HOMA-IR, and circulating free fatty acids, [Figure 3](#)). There was a clear reduction in systemic inflammatory markers, such as high-sensitivity C-reactive protein (−42% for 120 mg vs placebo; P = .161), fibrinogen, and haptoglobin at both doses ([Supplementary Figure 2A](#)). In line with the histologic changes, serum panel biomarkers of steatosis and fibrosis, such as SteatoTest, Fatty Liver Index, Fibrotest/FibroSure, and the NAFLD Fibrosis score, showed significant reductions in patients treated with elafibranor 120 mg compared with placebo ([Supplementary Figure 2B](#)).

Elafibranor was safe and well tolerated. Clinical adverse events were mostly mild and similar in the placebo and elafibranor arms ([Table 4](#)). There were no cardiovascular events or deaths in the elafibranor arms. Six patients (6.5%) were discontinued for adverse events in the placebo group, 7 (7.9%) in the 80-mg group, and 5 (5.4%) in the 120-mg groups. There was a mild, reversible but statistically significant increase in serum creatinine (effect size vs placebo: 4.31 ± 1.19 μmol/L; P < .001). Other renal markers, such as cystatin C and microalbuminuria, remained normal. The increase in creatinine led to a reported renal impairment/failure in 7 patients treated with elafibranor ([Supplementary Table 5](#)). All of them had increased creatinine at baseline; 1

Table 3. Response Rate and Main Analyses for the Modified Definition of Response in Patients With bNAS ≥4 and Various Stages of Fibrosis at Baseline

Population	Selection, n	Treatment arm, n (%)			OR (95% CI) ^a	P value ^a
		Placebo	Elafibranor 80 mg	Elafibranor 120 mg		
All NAS ≥4	234 ^b	76 (9)	83 (13)	75 (19)	3.52 (1.32–9.40)	.013
	202 ^c	63 (11)	72 (15)	67 (21)	3.26 (1.17–9.02)	.024
NAS ≥4 with fibrosis (any stage)	204 ^b	66 (11)	67 (15)	71 (20)	3.75 (1.39–10.12)	.009
	176 ^c	55 (13)	58 (17)	63 (22)	3.22 (1.15–8.99)	.026
NAS ≥4 with moderate/advanced fibrosis (F2, F3)	118 ^b	41 (7)	39 (10)	38 (13)	18.46 (4.80–70.96)	.0001
	99 ^c	32 (9)	33 (12)	34 (15)	10.59 (2.52–44.50)	.002

^a120 mg elafibranor vs placebo, direct treatment effect.

^bAll patients.

^cPatients with end of trial liver biopsy.




Figure 2. Changes from baseline in liver enzymes (A–C) and plasma lipids (D–F) in treatment groups of the Per Protocol set (n = 237). Results are expressed in mean values of changes from baseline during treatment with placebo (n = 77), elafibranor 80 mg (n = 82) and elafibranor 120 mg (n = 78). Error bars represent 95% CIs. ALT, alanine aminotransferase (A); Gamma-GT, γ -glutamyltranspeptidase (B). LDL, low-density lipoprotein.

of them had significant pre-existing increases in creatinine, cystatin C, urinary neutrophil gelatinase-associated lipocalin, urinary creatinine, serum albumin, and urinary albumin; and decreased creatinine clearance, and was therefore discontinued. Weight did not change and there was no significant reduction in hematocrit or hemoglobin vs placebo.

Serious adverse events occurred in 11 patients in the placebo (12%), 15 patients in the 80-mg (16.1%), and 14 patients in the 120-mg (15.8%) arms. Treatment-related serious adverse events occurred in 2 patients in the 80-mg elafibranor arm (spontaneous abortion, ataxia, fasciculation, and tremor), in 2 patients in the elafibranor 120 mg arm (acute




Figure 3. Elafibranor-induced changes in glucose homeostasis markers in type 2 diabetic patients. Type 2 diabetic patients account for 40% of the ITT population (n = 94). Mean changes vs baseline in elafibranor 80 mg (n = 31) and elafibranor 120 mg (n = 35) groups were compared with the changes in placebo group using a mixed model with group as fixed factor and baseline value as a covariate. The effect size compared with placebo was calculated and expressed as LS Mean. Error bars represent 95% CIs. # $P < .05$ vs placebo; ## $P < .01$ vs placebo. FFA, free fatty acids; FPG, fasting plasma glucose.

pancreatitis, Parkinson disease), and in 4 patients from the placebo arm (renal cancer, breast cancer, bladder cancer, and pancreatic cancer).

Neoplastic serious adverse events were reported in 6 patients during the study and the 3-month follow-up periods: one bladder cancer in the elafibranor 80-mg arm (unlikely related to study drug) in a patient with previous doubtful cytologic lesions, and 5 cancers in the placebo arm (the 4 described above and 1 esophageal cancer considered unlikely related to study drug).

Discussion

This randomized controlled trial provides evidence of efficacy of the dual PPAR α/δ activator elafibranor on both histologic reversal of NASH and metabolic improvement in patients with NASH. Both are important objectives on the path of controlling NASH. Steatohepatitis is indirectly associated with reduced hepatic survival in NAFLD.^{5,23} It drives fibrogenesis, a slow process of hepatic scar formation that can result in cirrhosis and its deadly complications, such as liver failure, portal hypertension, and hepatocellular

Table 4. Most Frequent Reported Treatment-Related Adverse Events

Adverse event	Elafibranor, 80 mg, n (%) (n = 93)	Elafibranor, 120 mg, n (%) (n = 89)	Placebo, n (%) (n = 92)	Total (n = 274)
Nausea	13 (13.98)	9 (10.11)	9 (9.78)	31 (11.31)
Headache	6 (6.45)	7 (7.87)	8 (8.7)	21 (7.66)
Diarrhea	6 (6.45)	5 (5.62)	4 (4.35)	15 (5.47)
Fatigue	5 (5.38)	5 (5.62)	4 (4.35)	14 (5.11)
Asthenia	4 (4.3)	0 (0)	2 (2.17)	6 (2.19)
Renal failure ^a	1 (1.08)	4 (4.49)	0 (0)	5 (1.82)
Renal impairment ^a	0 (0)	2 (2.25)	0 (0)	2 (0.73)
Abdominal pain	0 (0)	5 (5.62)	6 (6.52)	11 (4.01)
Abdominal pain, upper	1 (1.08)	3 (3.37)	3 (3.26)	7 (2.55)
Vomiting	5 (5.38)	3 (3.37)	2 (2.17)	10 (3.65)
Myalgia	5 (5.38)	2 (2.25)	2 (2.17)	9 (3.28)
Decreased appetite	3 (3.23)	5 (5.62)	0 (0)	8 (2.92)
Rash	3 (3.23)	4 (4.49)	1 (1.09)	8 (2.92)
Pruritus	1 (1.08)	1 (1.12)	2 (2.17)	4 (1.46)

^aTerm of adverse event as reported by the investigator, not based on any specific definition.

carcinoma. Consequently, clearance of steatohepatitis,²⁴ that is, reversal to a normal liver or to steatosis without steatohepatitis—a condition not associated with increased hepatic morbidity or mortality—is expected to improve hepatic prognosis and is now accepted as the best, short-term surrogate for histologic improvement in NASH trials.^{25,26}

When analyzed according to the a priori, protocol-defined primary outcome, there were no significant differences in treatment response between the 2 elafibranor groups and placebo. However, when using an updated, modified definition of reversal of NASH without worsening of fibrosis,^{19,20} the 120-mg elafibranor arm performed significantly better than placebo in the ITT population. The latter definition is more stringent than the one used in the protocol. First, it emphasizes hepatocyte ballooning, a sign of liver-cell injury and a cardinal feature of steatohepatitis that is associated with disease progression and enhanced fibrogenesis. In contrast, the protocol-based definition required the disappearance of either steatosis, inflammation, or hepatocyte ballooning. Second, based on older data showing that bridging fibrosis but not earlier stages is associated with liver-related mortality,^{23,27–29} only progression to bridging fibrosis (or to cirrhosis) was considered “worsening of fibrosis” in the protocol-based definition. Instead, the modified definition defines worsening of fibrosis as any one-stage increase based on recent data showing that even early fibrosis is associated with global and liver-related mortality.⁷ Importantly, this more stringent definition led to a lower placebo effect. Earlier studies have not explicitly defined reversal of NASH and subtle differences in the criteria used might explain the variable rates of response in the placebo group (from 13%²¹ to 21%¹¹). Therapeutics in NASH is an evolving field and previous trials have used an aggregate histologic score, the NAS, as a primary end point.^{11,21} However, the prognostic value of the NAS is not established.^{7,23,30} We expect that future, large phase 3 trials will be using this more

stringent definition of response and, therefore, we reported on both definitions of primary response in an attempt to facilitate comparisons of the magnitude of the effect both across trials and across classes of pharmacologic agents. Interestingly, for both definitions there was a significant interaction effect with baseline activity, suggesting that the latter is an important determinant of the efficacy of elafibranor.

Regardless of the definition of response, elafibranor at 120 mg was significantly superior to placebo in the post-hoc analysis after excluding the 15% of patients with mild steatohepatitis (ie, bNAS of 3). The 80-mg dose was not significantly better than placebo in any primary or secondary histologic analyses. Patients with mild but well-defined NASH were allowed to participate because of early concerns about recruitment feasibility, and because it was assumed that resolution of NASH was dependent on the presence of NASH and not on a particular level of severity. In these patients with mild steatohepatitis, there was an unexpectedly high placebo response rate that might have led to a lack of treatment effect in the planned primary outcome assessment. In addition, the observation that elafibranor is more efficient in more severe disease is consistent with recent data showing that hepatic PPAR α expression is reduced in advanced inflammatory and fibrotic NASH and that resolution of NASH is associated with a recovery of PPAR α expression.³¹ Whatever the explanation for the failure of elafibranor to significantly outperform placebo in patients with mild disease, it is important to note that these patients are usually not considered eligible for pharmacologic therapy, but rather should be managed through dietary and lifestyle changes. The 2 previous large trials in NASH that had NAS reduction as a primary outcome, only included patients with an NAS ≥ 4 ,^{11,21} and current practice for drug development is to include only patients with moderate or severe disease, defined by a NAS ≥ 4 . Similarly, it has been shown that fibrosis is a strong predictor of liver-related deaths⁷ and patients with fibrosis are at highest need for

pharmacotherapy. In secondary analyses of patients with moderate or severe NASH, 120 mg elafibranor was better than placebo, regardless of the presence or severity of fibrosis. The histologic benefit of the 120-mg dose was mirrored by a significant improvement in liver function tests, in particular alanine aminotransferase, γ -glutamyltransferase, and alkaline phosphatase, and in noninvasive serum panels of steatosis (Steatotest, Fatty Liver Index) and fibrosis (NAFLD Fibrosis score and Fibrotest), which are likely more sensitive and earlier response indicators than histology.

In order to randomize 270 patients, 56 sites were selected, with competitive recruitment and centralized randomization. Due to the unexpectedly high recruitment rates and the staggered design, treatment distribution across the sites was imbalanced. Patient recruitment ranged from 1 to 24 randomized patients per site, and only 15 sites had patients randomized in all 3 treatment arms. In an exploratory, post-hoc analysis designed to control for both center effect and baseline severity, the efficacy of 120 mg elafibranor was explored in the subset of patients with bNAS ≥ 4 from centers that randomized at least 1 patient per treatment arm. Both NASH resolution and a reduction by ≥ 2 points in the NAS were achieved more often than placebo. Interestingly, the 21% response rate of the placebo arm for a 2-point NAS reduction is comparable to previous studies,^{11,21} thus suggesting that this subgroup of the population is representative of patients included in previous trials.

Because prevention of the occurrence of cirrhosis is the ultimate goal, both from a clinical and a regulatory standpoint,²⁶ drug therapies for NASH should ideally impede fibrogenesis, either directly or indirectly, as a consequence of clearing steatohepatitis. Fibrosis reduction has been an elusive goal so far,^{11,32} but recently, a randomized trial of obeticholic acid reported a reduction in fibrosis stage over 18 months of therapy in NASH patients.²¹ The GOLDEN-505 trial was shorter and not designed for anti-fibrotic end points. It provided the proof-of-principle that resolution of steatohepatitis can result in improvement of fibrosis, an indirect anti-fibrotic effect. Responders for the primary end point, at the 120-mg elafibranor dose, experienced a significant reduction in fibrosis, which was not seen in the overall group of treated patients. Whether a direct anti-fibrotic potency of elafibranor, reported in experimental murine models of fibrosis,¹⁶ can be reproduced in humans deserves specific testing in longer trials. Future phase 3 trials will evaluate the effect of elafibranor on the rate of progression to cirrhosis as a result of the resolution of NASH or also through a direct anti-fibrotic effect.

An equally important aspect when treating patients with NASH is the requirement for absence of deterioration (or at best improvement) of the cardiometabolic comorbidities that contribute to overall mortality.^{25,26} In addition, insulin resistance, an almost constant feature of NASH, could be causally related to the hepatic buildup of fat, induction of lipotoxic compounds within the liver, and systemic and adipose tissue inflammation. All of these pathways

contribute to liver injury and fibrosis and, therefore, improving insulin sensitivity could also have beneficial effects on hepatic damage, as trials of pioglitazone have shown.⁹⁻¹¹ As expected from earlier phase 2 studies,^{17,18} including a hyperinsulinemic–euglycemic clamp study in insulin-resistant patients, elafibranor improved markers of insulin resistance, such as the HOMA-IR index, hyperinsulinemia, and free fatty acids, and also significantly reduced HbA1c in diabetics, which reflects improved glycemic control. The pro-atherogenic lipid profile of NASH patients was also improved with significant reductions of total and low-density lipoprotein cholesterol, and increases in HDL cholesterol at both elafibranor doses. Remarkably, the improvements in glycemic and lipid parameters were achieved in patients already treated with conventional glucose and lipid-lowering therapies, which suggests an additional, direct effect of PPAR α/δ agonism. It is interesting to note that contrary to placebo-induced resolution of NASH, patients that met the primary end point on elafibranor also exhibited a greater degree of improvement of metabolic and inflammatory parameters than nonresponders. The temporal interaction and dose dependency between the metabolic effects and the histologic response of elafibranor remains to be elucidated in larger trials.

Elafibranor showed a very good tolerability and safety profile throughout the 1-year exposure in this trial. This is of paramount importance, as NASH therapies are expected to be taken on a long-term basis. In addition, these patients often have asymptomatic liver disease and are therefore less willing to tolerate drug-induced side effects in the long term. There was a mild, isolated, and reversible increase in creatinine levels in some patients, and longer post-treatment follow-up is necessary to confirm the reversibility of this biologic effect. PPAR α agonists, such as fenofibrate, are known to induce reversible increases in serum creatinine without promoting renal failure, as a result of a pharmacodynamic effect.³³⁻³⁵ The mechanisms are not entirely known, but might involve increased skeletal muscle production. An improvement in renal function upon fibrate treatment has been reported in a meta-analysis³⁶ that described a reduction in albuminuria progression. Here, the increase in creatinine was lower than that observed with fenofibrate (7.1% with 120 mg elafibranor vs 17.2% with fenofibrate; a $>20\%$ increase in half of the treated population from the ACCORD [Action to Control Cardiovascular Risk in Diabetes] trial³⁴). However, the absence of an adverse effect of elafibranor on renal function in patients with NASH should be confirmed in larger trials.

This trial has several other strengths and some limitations. The rigorous centralized pathologic reading for both inclusion and end-of-treatment biopsies avoided inclusion of patients without clearly defined NASH,²⁴ and provided uniformity and lack of inter-observer variability for the assessment of histologic end points. The proportion of screen failures for histology was low, thus ensuring that included patients were representative of most real-life NASH patients seen in tertiary centers. Likewise, the low proportion of missing end-of-treatment biopsies minimized

potential biases due to patient retention. Another strength is that this was the first large, international, multicenter trial in NASH. However, there were also methodologic limitations. The staggered design of the trial could have resulted in unequal access to the 3 treatment arms, as the randomization sequence was not set upfront for the 3 arms. The competitive recruitment resulted in a variable number of included patients in each center and in an uneven distribution between treatment arms that contributed to a significant center effect. Finally, the inclusion of patients with mild steatohepatitis (bNAS 3) might have blunted the effect of elafibranor in the overall ITT population, as it resulted in a high placebo response rate. Nonetheless, the size of the trial allowed exploratory subgroup analyses that strengthened the demonstration of efficacy. Although secondary analyses are to be considered with caution, this was not a registration, phase 3 trial, but a proof-of-concept, phase 2b exploratory trial designed to inform the design of subsequent, larger, pivotal studies.

The results of this trial compare favorably with results of other investigational agents tested in comparable trials. For instance in the FLINT (Farnesoid X Receptor (FXR) Ligand Obeticholic Acid in NASH Treatment) trial, obeticholic acid induced resolution of NASH in 22% of patients vs 13% in the placebo group. The difference became significant in a post-hoc analysis of the subset of patients with well-defined steatohepatitis at baseline: 19% vs 8%, respectively ($P < .05$). These rates of response are very close to those obtained in the current trial in the ITT population and in the subset with $\text{NAS} \geq 4$ (all FLINT participants had an $\text{NAS} \geq 4$). In post-hoc analyses from the subgroup of patients with well-defined NASH in the PIVENS (Pioglitazone vs Vitamin E vs Placebo for Treatment of Non-Diabetic Patients With Nonalcoholic Steatohepatitis) trial, pioglitazone induced resolution of steatohepatitis in 47% of patients (21% for placebo; $P = .001$) and vitamin E in 36% ($P = .05$). Direct comparisons between molecules are misleading in the absence of head-to-head trials, and because of differences in inclusion criteria and in definitions of histologic response. Importantly, a detailed definition of “resolution of steatohepatitis” is not available from FLINT or PIVENS. In addition, there was no requirement for the absence of “worsening of fibrosis” when defining resolution of NASH as an end point for either PIVENS or FLINT, which further limits comparisons between rates of response with the GOLDEN-505 trial. Only large, phase 3 trials will provide reliable estimates of treatment response for obeticholic acid and elafibranor, but what is clear so far is that a majority of patients are nonresponders and that additional pharmacologic strategies will be necessary to optimize the response rate.

In conclusion, this randomized controlled trial provides evidence that pharmacologic modulation of the $\text{PPAR}\alpha/\delta$ nuclear receptors results in substantial histologic improvement in NASH, including resolution of steatohepatitis and improvement of the cardiometabolic risk profile, with a favorable safety profile. Larger phase 3 trials of elafibranor in the target population of patients with moderate to severe NASH are warranted.

Supplementary Material

Note: To access the supplementary material accompanying this article, visit the online version of *Gastroenterology* at www.gastrojournal.org, and at <http://dx.doi.org/10.1053/j.gastro.2016.01.038>.

References

1. Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. *Hepatology* 2012;55:2005–2023.
2. Ratziu V, Bellentani S, Cortez-Pinto H, et al. A position paper on NAFLD/NASH based on the EASL 2009 Special Conference. *J Hepatol* 2010;53:372–384.
3. Vernon G, Baranova A, Younossi ZM. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. *Aliment Pharmacol Ther* 2011;34:274–285.
4. Charlton MR, Burns JM, Pedersen RA, et al. Frequency and outcomes of liver transplantation for nonalcoholic steatohepatitis in the United States. *Gastroenterology* 2011;141:1249–1253.
5. Ekstedt M, Franzen LE, Mathiesen UL, et al. Long-term follow-up of patients with NAFLD and elevated liver enzymes. *Hepatology* 2006;44:865–873.
6. Yki-Jarvinen H. Non-alcoholic fatty liver disease as a cause and a consequence of metabolic syndrome. *Lancet Diabetes Endocrinol* 2014;2:901–910.
7. Angulo P, Kleiner DE, Dam-Larsen S, et al. Liver fibrosis, but no other histologic features, associates with long-term outcomes of patients with nonalcoholic fatty liver disease. *Gastroenterology* 2015;149:389–397.
8. Ekstedt M, Hagstrom H, Nasr P, et al. Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. *Hepatology* 2015;61:1547–1554.
9. Belfort R, Harrison SA, Brown K, et al. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. *N Engl J Med* 2006;355:2297–2307.
10. Aithal GP, Thomas JA, Kaye PV, et al. Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis. *Gastroenterology* 2008;135:1176–1184.
11. Sanyal AJ, Chalasani N, Kowdley KV, et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. *N Engl J Med* 2010;362:1675–1685.
12. Pawlak M, Lefebvre P, Staels B. Molecular mechanism of $\text{PPAR}\alpha$ action and its impact on lipid metabolism, inflammation and fibrosis in non-alcoholic fatty liver disease. *J Hepatol* 2015;62:720–733.
13. Bojic LA, Huff MW. Peroxisome proliferator-activated receptor δ : a multifaceted metabolic player. *Curr Opin Lipidol* 2013;24:171–177.
14. Odegaard JI, Ricardo-Gonzalez RR, Red Eagle A, et al. Alternative M2 activation of Kupffer cells by $\text{PPAR}\delta$ ameliorates obesity-induced insulin resistance. *Cell Metab* 2008;7:496–507.

15. Riserus U, Sprecher D, Johnson T, et al. Activation of peroxisome proliferator-activated receptor (PPAR) δ promotes reversal of multiple metabolic abnormalities, reduces oxidative stress, and increases fatty acid oxidation in moderately obese men. *Diabetes* 2008; 57:332–339.
16. Staels B, Rubenstrunk A, Noel B, et al. Hepatoprotective effects of the dual peroxisome proliferator-activated receptor α/δ agonist, GFT505, in rodent models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. *Hepatology* 2013;58:1941–1952.
17. Cariou B, Hanf R, Lambert-Porcheron S, et al. Dual peroxisome proliferator-activated receptor α/δ agonist GFT505 improves hepatic and peripheral insulin sensitivity in abdominally obese subjects. *Diabetes Care* 2013;36:2923–2930.
18. Cariou B, Zair Y, Staels B, et al. Effects of the new dual PPAR α/δ agonist GFT505 on lipid and glucose homeostasis in abdominally obese patients with combined dyslipidemia or impaired glucose metabolism. *Diabetes Care* 2011;34:2008–2014.
19. Kleiner DE, Bedossa P. Liver histology and clinical trials for nonalcoholic steatohepatitis—perspectives from 2 pathologists. *Gastroenterology* 2015;149:1305–1308.
20. Armstrong MJ, Gaunt P, Aithal GP, et al. Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study. *Lancet* 2016; 387(10019):679–690.
21. Neuschwander-Tetri BA, Loomba R, Sanyal AJ, et al. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. *Lancet* 2015;385(9972):956–965.
22. Tamhane AC, Hochberg Y, Dunnett CW. Multiple test procedures for dose finding. *Biometrics* 1996;52:21–37.
23. Younossi ZM, Stepanova M, Rafiq N, et al. Pathologic criteria for nonalcoholic steatohepatitis: Interprotocol agreement and ability to predict liver-related mortality. *Hepatology* 2011;53:1874–1882.
24. Ratziu V, Caldwell S, Neuschwander-Tetri BA. Therapeutic trials in nonalcoholic steatohepatitis: insulin sensitizers and related methodological issues. *Hepatology* 2010;52:2206–2215.
25. Sanyal AJ, Brunt EM, Kleiner DE, et al. Endpoints and clinical trial design for nonalcoholic steatohepatitis. *Hepatology* 2011;54:344–353.
26. Sanyal AJ, Friedman SL, McCullough AJ, et al. Challenges and opportunities in drug and biomarker development for nonalcoholic steatohepatitis: findings and recommendations from an American Association for the Study of Liver Diseases-U.S. Food and Drug Administration Joint Workshop. *Hepatology* 2015;61: 1392–1405.
27. Everhart JE, Wright EC, Goodman ZD, et al. Prognostic value of Ishak fibrosis stage: findings from the HALT-C trial. *Hepatology* 2009;51:585–594.
28. Parkes J, Roderick P, Harris S, et al. Enhanced liver fibrosis test can predict clinical outcomes in patients with chronic liver disease. *Gut* 2010;59:1245–1251.
29. Imazeki F. Favorable prognosis of chronic hepatitis C after interferon therapy by long-term cohort study. *Hepatology* 2003;38:493–502.
30. Ekstedt M, Franzen LE, Mathiesen UL, et al. Low clinical relevance of the nonalcoholic fatty liver disease activity score (NAS) in predicting fibrosis progression. *Scand J Gastroenterol* 2012;47:108–115.
31. Francque S, Verrijken A, Caron S, et al. PPAR α gene expression correlates with severity and histological treatment response in patients with non-alcoholic steatohepatitis. *J Hepatol* 2015;63:164–173.
32. Lavine JE, Schwimmer JB, Van Natta ML, et al. Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial. *JAMA* 2011;305:1659–1668.
33. Ting RD, Keech AC, Drury PL, et al. Benefits and safety of long-term fenofibrate therapy in people with type 2 diabetes and renal impairment: the FIELD Study. *Diabetes Care* 2012;35:218–225.
34. Bonds DE, Craven TE, Buse J, et al. Fenofibrate-associated changes in renal function and relationship to clinical outcomes among individuals with type 2 diabetes: the Action to Control Cardiovascular Risk in Diabetes (ACCORD) experience. *Diabetologia* 2012; 55:1641–1650.
35. Davis TM, Ting R, Best JD, et al. Effects of fenofibrate on renal function in patients with type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study. *Diabetologia* 2011; 54:280–290.
36. Jun M, Foote C, Lv J, et al. Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis. *Lancet* 2010;375(9729):1875–1884.

Received October 19, 2015. Accepted January 29, 2016.

Reprint requests

Address requests for reprints to: Vlad Ratziu, MD, PhD, Université Pierre et Marie Curie, Hospital Pitié Salpêtrière, 47-83 Bd d'el'Hôpital, Paris, France 75013. e-mail: vlad.ratziu@upmc.fr; fax: +33142161042.

Acknowledgments

The view(s) expressed herein are those of the author(s) and do not reflect the official policy or position of San Antonio Military Medical Center, the U.S. Army Medical Department, the U.S. Army Office of the Surgeon General, the Department of the Army, Department of Defense or the U.S. Government.

Genfit expresses its gratitude to the Data and Safety Monitoring Board members, Professors Eric Bruckert, Chris Day, Jean-François Dufour, and Nikolaus Marx for their guidance on the safety conduct of the trial, to all study staff who contributed to patient recruitment and follow-up, and to the patients enrolled in the GOLDEN-505 trial. We would also like to acknowledge John Brozek, Emilie Praca, and Fouad Ben Sudrik for their contribution to the statistical analyses.

GOLDEN-505 Investigator Study Group: P. Mathurin, Claude Huriez Hospital, Lille, France; J. Gournay, Nantes Hospital, Nantes, France; E. Nguyen-Khac, Amiens Picardie Hospital, Salouel, France; V. De Ledinghen, Haut-Leveque Hospital, Pessac, France; D. Larrey, Saint Eloi Hospital, Montpellier, France; A. Tran, Nice Hospital, Nice, France; M. Bourliere, Saint Joseph Hospital, Marseille, France; M. Maynard-Muet, Lyon Hospital, Lyon, France; T. Asselah, Beaujon Hospital, Paris, France; J. Henrion, Haine-Saint-Paul Hospital, Jolimont, Belgium; F. Nevens, Leuven UZ, Leuven, Belgium; D. Cassiman, Leuven UZ, Leuven, Belgium; A. Geerts, Gent UZ, Gent, Belgium; C. Moreno, Erasme Hospital, Brussels, Belgium; U. H. Beuers, AMC Amsterdam, The Netherlands; P. R. Galle, Mainz Medical Clinic, Mainz, Germany; U. Spengler, Polyclinic Bonn, Germany; E. Bugianesi, San Giovanni Battista Hospital, Torino, Italy; A. Craxi, University Hospital Paolo Giaccone, Palermo, Italy; M. Angelico, Polyclinic Fondazione Tor Vergata, Rome, Italy; S. Fargion, Fondazione IRCCS, Milano, Italy; M. Voiculescu, Clinic Fundeni, Bucharest, Romania; L. Gheorghe, Clinic

Fundeni, Bucharest, Romania; L. Preotescu, National Institute Boli Infectioase, Bucharest, Romania; J. Caballeria, Clinic Hospital, Barcelona, Spain; R. J. Andrade, University Hospital Virgen de la Victoria, Malaga, Spain; J. Crespo, University Hospital Marques de Valdecilla, Santander, Spain; J. L. Callera, University Hospital Puerta De Hierro De Majadahonda, Majadahonda, Spain; A. Ala, Frimley Park Hospital, Camberley, UK; G. Aithal, Nottingham Digestive Diseases Center, Nottingham, UK; G. Abouda, Hull and East Yorkshire Hospitals, Hull, UK; V. Luketic, Virginia Commonwealth Hospital, Richmond, VA, USA; M. A. Huang and S. Gordon, Henry Ford Hospital, Detroit, MI, USA; P. Pockros, Scripps Clinic Torrey Pines, La Jolla, CA, USA; F. Poordad, The Texas Liver Institute, San Antonio, TX, USA; N. Shores and M. W. Moehlen, Tulane University Health Sciences Center, New Orleans, LA, USA; K. Bambha, University of Colorado, Aurora, CO, USA; V. Clark, University of Florida, Gainesville, FL, USA; S. Satapathy, Methodist University Hospital, Memphis, TN, USA; S. Parekh, Emory University Hospital, Atlanta, GA, USA; R. K. Reddy, Hospital of the University of Pennsylvania, Philadelphia, PA, USA; M. Y. Sheikh, UCSF, Fresno, CA, USA; G. Szabo, University of Massachusetts Memorial Medical Center, Worcester, MA, USA; J. Vierling, St Luke's Episcopal Hospital, Houston, TX, USA; T. Foster, Grady Memorial Hospital, Atlanta, GA, USA; G. Umpierrez, Emory University School of Medicine, Atlanta, GA, USA; C. Chang, Mount Sinai School of Medicine, New York, NY, USA; T. Box and J. Gallegos-Orozco, University of Utah, Salt Lake City, UT, USA.


Conflicts of interest

These authors disclose the following: VR reports consulting fees from Abbott, Astra-Zeneca, Boehringer-Ingelheim, Galmed, Genfit, Nimbus, Ionis, Pfizer Novartis, Roche-Genentech, Intercept, Sanofi Aventis-Genzyme, Takeda, Tobira, and research support from the European Community's Seventh Framework Programme (FP7/2007-2013) under grant agreement number HEALTH-F2-2009-241762 for the project FLIP. SH reports consulting fees from AbbVie, Astra Zeneca, Galectin, Genfit, Nitto Denko, Nimbus, Salix,


Tobira. SF reports consulting and speaker fees from MSD, Roche, Gilead, BMS, Astellas, Synageva, Genfit, Actelion, Fresenius, Abbvie. PL reports consulting fees from Genfit. LS has served on consulting, advisory committees or review panels for Abbvie, Janssen, Merck Sharp & Dohme (MSD), Roche, Bristol-Meyers Squibb (BMS), Gilead, Intercept, GlaxoSmithKline (GSK), Pfizer and Novartis and has received grant/research support from Roche and MSD and provided speaking and teaching for Roche, Abbvie, MSD, Gilead, BMS, Janssen and Aptalis. MRG reports consulting fees from Merck, Roche, Gilead, Abbvie, Janssen, BMS, Idenix, Ocera, Umecline and research support from Merck, Roche, Gilead; MA received consulting fees from Taiwan J Pharmaceuticals, Islet Sciences and research/grant funding from the National Institutes of Health/National Institute of Diabetes and Digestive and Kidney Diseases, Gilead Sciences, Taiwan J Pharma, Tobira, Immuron, Galmed, Arisaph Pharma, Intercept Pharma, Galactin, BMS, NGM, Synageva, Metabolon, and Genfit. SC reports consulting fees from Vital Therapy, Welstat, and research support from Gilead, Genfit, NGM, Taiwan J, Galmed, Immuron, Hyperion, Salix. JD reports consulting fees from BMS, Gilead, Janssen, and Merck and research grants from Abbvie and Janssen, all fees directed toward the Radboudumc Foundation. QA reports consulting fees for consultancy on behalf of Newcastle University from Genfit, Acuitas Medical, Intercept, Raptor Pharma, NewGene, and speaker fees from Abbott and Falk and research funding from GSK and Vertex. DH, RH, AR, SM are employees of Genfit SA. BS is a consultant of Genfit. AS has stock options in Genfit. He has served as a consultant to AbbVie, Astra Zeneca, Nitto Denko, Nimbus, Salix, Tobira, Takeda, Fibrogen, Immuron, Exalenz, and Genfit. He has been an unpaid consultant to Intercept and Echosens. His institution has received grant support from Gilead, Salix, Tobira, and Novartis. The remaining authors disclose no conflicts.

Funding

The study was funded by Genfit SA.



Supplementary Figure 1. Overall improvement in liver histology in patients who achieved the primary outcome according to the modified definition of response in the elafibranor 120-mg arm. Results are expressed as mean values of changes from baseline during treatment in responders (n = 17) and nonresponders (n = 61) to elafibranor 120 mg. Error bars represent 95% CIs. **P* < .05; ***P* < .01; ****P* < .001.



Supplementary Figure 2. Changes from baseline in inflammatory markers (Sup2A) and in noninvasive scores of fibrosis and steatosis (Sup2B) in treatment groups in the per protocol analysis (n = 237). Results are expressed as mean values of changes from baseline during treatment with placebo (n = 77), elafibranor 80 mg (n = 82) and elafibranor 120 mg (n = 78). Error bars represent 95% CIs. **P* < .05; ***P* < .01; ****P* < .001 vs baseline. #*P* < .05; ##*P* < .01; ###*P* < .001 vs placebo.

Supplementary Table 1. Reasons for Dropout From the Trial
(n = 33 [12%])

Reason for dropout during the trial	n (%)
Adverse events	17 (51.5)
Consent withdrawal	11 (33.3)
Lost to follow-up	1 (3)
Noncompliance	2 (6)
Protocol withdrawal criteria	2 (6)

Supplementary Table 2. Interaction Effect Between Treatment and bNAS in the ITT Population (n = 274 patients) With Protocol-Defined and the Modified Definitions of the Primary Outcome

Elafibranor dose	Protocol-defined definition			Modified definition		
	OR (95% CI)	RR (95% CI)	<i>P</i> (OR)	OR (95% CI)	RR (95% CI)	<i>P</i> (OR)
80 mg	1.80 (0.85–3.82)	1.61 (0.88–2.92)	.125	1.28 (0.57–2.86)	1.24 (0.64–2.40)	.551
120 mg	2.63 (1.25–5.52)	2.09 (1.16–3.77)	.012	2.76 (1.33–5.76)	2.23 (1.24–4.03)	.007

RR, relative risk.

Supplementary Table 3. Secondary Histologic End Points: Descriptive Analyses of Improvement in Histologic Lesions According to Baseline NAS Severity in the ITT Population (n = 274)

Variable	Baseline severity (bNAS), n	Placebo, %	Elafibranor, 80 mg, %	Elafibranor, 120 mg, %
NAS 2-point reduction	Severe (6–8), 90	23	28	40
	Moderate (4–5), 144	20	20	27
	Mild (3), 40	31	20	14
Steatosis	Severe (6–8), 90	10	10	33
	Moderate (4–5), 144	27	24	22
	Mild (3), 40	0	10	7
Hepatocyte ballooning	Severe (6–8), 90	16	34	40
	Moderate (4–5), 144	29	31	33
	Mild (3), 40	38	40	21
Lobular inflammation	Severe (6–8), 90	39	48	53
	Moderate (4–5), 144	18	19	24
	Mild (3), 40	44	10	14

Supplementary Table 4. Histologic Changes in Patients With Moderate/Severe NASH (bNAS \geq 4) Randomized in Centers That Included in Each Treatment Arm (n = 120)

Variable	Placebo (n = 39)	Elafibranor, 80 mg (n = 50)	Elafibranor, 120 mg (n = 31)	P value (120 mg vs placebo)
Resolution of NASH (without worsening of fibrosis), ^a %	5	8	26	.02
Resolution of NASH (without worsening of fibrosis), ^b %	5	18	29	.01
Decrease of NAS \geq 2, %	21	18	48	.01
Mean change in NAS score	-0.38	-0.38	-1.1	.02
Steatosis ^c				
Patients with decrease of at least 1 point	18	14	35	.10
Change in score	0.03	0.10	-0.13	.35
Hepatic ballooning ^c				
Patients with decrease of at least 1 point	23	26	45	.02
Change in score	-0.15	-0.22	-0.45	.01
Lobular inflammation ^c				
Patients with decrease of at least 1 point	33	30	55	.05
Change in score	-0.26	-0.26	-0.52	.10

^aAccording to the modified definition of resolution of NASH without worsening of fibrosis.

^bAccording to the protocol-defined primary outcome.

^cAdjusted for baseline severity of steatosis, ballooning and inflammation, respectively, at baseline.

Supplementary Table 5. Individual Data for Creatinine and Creatinine Clearance in Patients With Treatment-Associated Increases in Serum Creatinine

ID (site/patient)	Sex	Creatinine, <i>mg/dL</i>							Elafibranor treatment arm
		V2	V3	V4	V5	V6	V7	V8	
203/01	M	1.13	1.27	1.36	1.27	1.30	1.28	1.17	120 mg
302/04	F	0.93	1.16	1.17	1.14	1.17	1.17	1.08	80 mg
302/05	M	1.06	1.50	1.32	1.28	1.19	1.35	1.21	120 mg
302/06	M	0.89	0.90	1.16	1.09	1.02	1.09	1.20	120 mg
303/03	F	0.92	1.00	1.07	1.07	1.08	1.14	1.05	120 mg
902/05	M	1.38	1.64	1.53	1.67	2.02	0.00	1.59	120 mg
916/03	F	1.33	1.41	1.34	1.25	1.26	1.41	1.25	120 mg

ID (site/patient)	Sex	Creatinine clearance, <i>mL/min</i>							
		V1	V2	V3	V4	V5	V6	V7	V8
203/01	M	60	60	59	55	59	58	59	60
302/04	F	60	60	48	47	49	47	47	52
302/05	M	60	60	47	55	57	60	53	60
302/06	M	60	60	60	60	60	60	60	60
303/03	F	60	60	56	52	52	51	48	53
902/05	M	57	52	43	46	42	33	—	44
916/03	F	58	50	46	49	53	53	46	53

F, female; M, male; V, protocol-defined patient visits.